Clene Inc. is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic ...

Clene Inc. (NASDAQ ... The company’s presentation will be given by CEO Rob Etherington and CFO Morgan Brown. The presentation starts at 1 p.m. ET. Anyone interested in participating can register ...

Clene's presentation by CEO Rob Etherington and CFO Morgan Brown is ... Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and ...

SALT LAKE CITY, March 24, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq ... analyses in the third quarter,” said Rob Etherington, President and CEO of Clene. “Our goal from these additional ...

Clene, Inc. reports significant survival ... Phase 3 RESTORE-ALS study in mid-2025,” stated Rob Etherington, President and CEO of Clene. “We look forward to discussing these findings with ...

SALT LAKE CITY - March 25, 2025 (NEWMEDIAWIRE) - Clene Inc. (NASDAQ ... that fosters productive conversations," said Rob Etherington, CEO and President of Clene. "JonesTrading is pleased to ...

Clene plans to submit a New Drug Application ... the resulting analyses in the third quarter,” said Rob Etherington, President and CEO of Clene. “Our goal from these additional analyses ...

President and CEO of Clene (CLNN). “Our goal from these additional analyses is to determine concordance of the NIH-sponsored EAP NfL data with NfL results in our HEALEY Platform Trial.